ONE YEAR WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE

4CPS-259
ATC: J05
Gutiérrez-Lorenzo M1, Urda-Romacho J1, Rubio-Calvo D1, Castro-Vida MA1, Pinto-Nieto CM1
1: Agencia pública sanitaria Poniente (Almería), Hospital Pharmacy Service

BACKGROUND
Therapies for Human immunodeficiency virus (HIV) are continuously renewing. For these reason Antiretroviral treatment (ART) for HIV patients should be individualized. Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in fixed-dose combination is a new ART that has been approved.

AIM AND OBJECTIVES
To assess efficacy and safety at 24 weeks of BIC/FTC/TAF in naïve patients and patients switching to BIC/FTC/TAF.

MATERIAL AND METHODS
DESIGN: observational retrospective study
STUDY TIME: 2019-2020
PARTICIPANTS: HIV patients (naïve or switching) treated with BIC/FTC/TAF for at least 24 weeks

RESULTS
95 patients were included
25 Naïve
Mean age: 40 years
70 Switching
Mean age: 43 years

Analytical data at BASELINE
Median VL 764,026 copies/ml
Median VL 120,413 copies/ml
Median CD4 402 cells/ml
Median CD4 639 cells/ml

Analytical data AFTER 24 WEEKS
Undetectable VL
Median CD4: 736 cells/ml
Detectable VL
Median CD4: Non valueable

SAFETY
11 patients in both groups reported AE to BIC/FTC/TAF

CONCLUSIONS
✔ BIC/FTC/TAF Proved to be effective and safe in both naïve and switch patients
✔ All AE reported during the study were mild and with a low incidence

Contact: Daniel.rubio@ephpo.es

BACKGROUND AIM AND OBJECTIVES
Therapies for Human immunodeficiency virus (HIV) are continuously renewing. For these reason Antiretroviral treatment (ART) for HIV patients should be individualized. Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in fixed-dose combination is a new ART that has been approved.

To assess efficacy and safety at 24 weeks of BIC/FTC/TAF in naïve patients and patients switching to BIC/FTC/TAF.

MATERIAL AND METHODS
DESIGN: observational retrospective study
STUDY TIME: 2019-2020
PARTICIPANTS: HIV patients (naïve or switching) treated with BIC/FTC/TAF for at least 24 weeks

RESULTS
95 patients were included
25 Naïve
Mean age: 40 years
70 Switching
Mean age: 43 years

Analytical data at BASELINE
Median VL 764,026 copies/ml
Median VL 120,413 copies/ml
Median CD4 402 cells/ml
Median CD4 639 cells/ml

Analytical data AFTER 24 WEEKS
Undetectable VL
Median CD4: 736 cells/ml
Detectable VL
Median CD4: Non valueable

SAFETY
11 patients in both groups reported AE to BIC/FTC/TAF

CONCLUSIONS
✔ BIC/FTC/TAF Proved to be effective and safe in both naïve and switch patients
✔ All AE reported during the study were mild and with a low incidence

Contact: Daniel.rubio@ephpo.es